mHealth apps reduce HbA1c by 0.39% in type 2 diabetes across 19 RCTsMobile Health Apps Help Manage Blood Sugar in Type 2 Diabetes

Frontiers in Medicine Published July 30, 2026 Study authors: Mingli Li, Shili Yang, Shuang Hu, Yanhui Chang, Xiangrong Liu DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider mHealth apps as an adjunct to standard care for improving glycemic control and quality of life in type 2 diabetes.

This meta-analysis of 19 randomized controlled trials involving 2,166 participants with type 2 diabetes mellitus (T2DM) evaluated the impact of mobile health (mHealth) application interventions compared to control interventions. The primary outcome was glycated hemoglobin (HbA1c), and secondary outcomes included fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPBG), lipid profile, quality of life, and diabetes distress.

mHealth interventions significantly reduced HbA1c (mean difference [MD] -0.39, 95%CI -0.49 to -0.30), FBG (MD -0.68, 95%CI -0.89 to -0.46), and 2hPBG (MD -1.46, 95%CI -1.90 to -1.02). Total cholesterol also decreased (MD -0.21, 95%CI -0.38 to -0.05). Quality of life improved (SMD 0.24, 95%CI 0.02 to 0.47), and diabetes distress was reduced (SMD -0.22, 95%CI -0.38 to -0.05).

No statistically significant differences were observed for triglycerides, HDL-C, or LDL-C. The authors note that effects on lipid metabolism require further investigation. Adverse events and follow-up duration were not reported.

These findings suggest that mHealth apps can improve glycemic control and quality of life in T2DM, though their impact on lipids remains uncertain. Clinicians may consider mHealth as a complementary tool, but further research is needed to clarify long-term benefits and lipid outcomes.

How this fits prior evidence

This meta-analysis extends prior evidence on T2DM management by showing that mHealth apps improve glycemic control (HbA1c reduction of 0.39%) and quality of life, complementing findings on SGLT2 inhibitors reducing body fat and GLP-1 receptor agonists lowering cancer risk. It addresses a gap in digital interventions, though effects on lipids were not significant, contrasting with the metabolic benefits seen with SGLT2 inhibitors. The results align with the role of insulin resistance in T2DM but do not directly address biological aging or gut microbiota.

A large review of 19 clinical trials involving over 2,000 people found that using mobile health (mHealth) applications can help manage type 2 diabetes. The study specifically looked at how these apps affected blood sugar levels, cholesterol, and the daily stress of living with the condition.

The data showed that patients who used these mobile tools had significantly lower HbA1c, fasting blood glucose, and 2-hour postprandial blood glucose levels compared to those who did not. Additionally, participants reported a better quality of life and felt less distress regarding their diabetes diagnosis.

While the apps helped with blood sugar and stress, they did not show a significant effect on certain cholesterol markers like triglycerides or LDL and HDL levels. Because this was a review of many different trials, it is important to remember that individual results may vary. Talk to your doctor about how mobile tools might fit into your specific treatment plan.

What this means for you:

Mobile health apps can help lower blood sugar and reduce stress for people with type 2 diabetes.

Common questions

Can a mobile app actually help my blood sugar?

Yes, this review of 19 trials involving 2,166 participants found that mHealth applications significantly reduced HbA1c and fasting blood glucose levels. These results suggest that using these tools can be an effective way to manage the primary markers of type 2 diabetes.

Does using a health app reduce the stress of having diabetes?

The study found that patients using mobile health applications reported a better quality of life and experienced less diabetes distress. This suggests that these tools can help improve the daily experience of managing your condition.

Will these apps help lower my cholesterol levels?

While the app helped with blood sugar, it did not show a statistically significant difference in triglyceride or HDL and LDL cholesterol levels. More research is needed to understand how these apps affect lipid metabolism specifically.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJul 2026

View Original Abstract ↓

This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to comprehensively assess the impact of mobile health (mHealth) application interventions on glycolipid metabolism and quality of life among patients with type 2 diabetes mellitus (T2DM). A comprehensive search was conducted across major English- and Chinese-language electronic databases, including PubMed, Embase, the Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP, and the Chinese Biomedical Literature Database, using a combination of MeSH terms and free words. The search period extended from the inception of each database to 12 March 2026. RCTs evaluating mHealth application interventions for T2DM were included. The risk of bias was assessed using the Cochrane risk of bias tool. Statistical analyses and heterogeneity tests were performed using Review Manager 5.4 and Stata 18.0. The primary outcome was glycated hemoglobin. The secondary outcomes included fasting blood glucose (FBG), 2-h postprandial blood glucose (2hPBG), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), quality of life, and diabetes distress. A total of 19 RCTs comprising 2,166 participants were included. The meta-analysis showed that, compared to control interventions, mHealth application-based management significantly reduced HbA1c [MD = −0.39, 95%CI: −0.49, −0.30], FBG [MD = −0.68, 95%CI: −0.89, −0.46], 2hPBG [MD = −1.46, 95%CI: −1.90, −1.02], and TC levels [MD = -0.21, 95%CI: −0.38, −0.05]. The intervention also improved quality of life [SMD = 0.24, 95%CI: 0.02, 0.47] and reduced diabetes distress [SMD = −0.22, 95%CI: −0.38, −0.05]. However, no statistically significant differences were observed between the groups regarding TG, HDL-C, or LDL-C levels. mHealth applications positively influence glucose metabolism and quality of life in patients with T2DM; however, their effects on lipid metabolism require further investigation. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261354082, Unique Identifier: CRD420261354082.

mHealth apps reduce HbA1c by 0.39% in type 2 diabetes across 19 RCTsMobile Health Apps Help Manage Blood Sugar in Type 2 Diabetes

How this fits prior evidence

Common questions

Study Details

AI-OCT reports reduced false-positive DME referral rates from 69.1% to 24.1%

AI technology reduces unnecessary referrals for diabetic macular edema

Clinical research that matters. Delivered to your inbox.

mHealth apps reduce HbA1c by 0.39% in type 2 diabetes across 19 RCTsMobile Health Apps Help Manage Blood Sugar in Type 2 Diabetes

How this fits prior evidence

Common questions

More on Type 2 Diabetes Mellitus

Study Details

AI-OCT reports reduced false-positive DME referral rates from 69.1% to 24.1%

AI technology reduces unnecessary referrals for diabetic macular edema

Clinical research that matters. Delivered to your inbox.

Related in Diabetes & Endocrinology

From Other Specialties